3-碘-4-甲基苯甲酸甲酯 | 90347-66-3

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-碘-4-甲基苯甲酸甲酯
• 英文名称: methyl 3-iodo-4-methylbenzoate
• 英文别名: 3-iodo-4-methylbenzoic acid methyl ester；methyl 3‐iodo‐4‐methylbenzoate
• CAS: 90347-66-3
• 化学式: C₉H₉IO₂
• 分子量: 276.074
• InChiKey: NKMHAOTZPFVSPC-UHFFFAOYSA-N

物化性质

• 沸点：
  302.9±30.0 °C(Predicted)
• 密度：
  1.666±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  按规定使用和贮存的不会分解，避免接触氧化物和光照。

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090
• 危险品标志：
  Xi
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H315,H319
• 储存条件：
  存于密闭、阴凉、干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
methyl 3-iodo-4-methylbenzoate
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P362: Take off contaminated clothing and wash before reuse
P321: Specific treatment (see on this label)
P332+P313: If skin irritation occurs: Get medical advice/attention
P337+P313: If eye irritation persists get medical advice/attention

---

Section 3. Composition/information on ingredients.
methyl 3-iodo-4-methylbenzoate
Ingredient name:
CAS number: 90347-66-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H9IO2
Molecular weight: 276.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-碘-4-甲基苯甲酸甲酯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 potassium tert-butylate 、 三乙胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 23.0h， 生成 4-甲基-N-[4-[(4-甲基-1-哌嗪基)甲基]-3-(三氟甲基)苯基]-3-[2-(1H-吡唑并[3,4-b]吡啶-5-基)乙炔基]苯甲酰胺
  参考文献：
  名称：

  Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region–Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib

  摘要：

  Bcr-Abl(T315)I mutation-induced imatinib resistance remains a major challenge for clinical management of chronic myelogenous leukemia (CML). Herein, we report GZD824 (10a) as a novel orally bioavailable inhibitor against a broad spectrum of Bcr-Abl mutants including T315I. It tightly bound to Bcr-Abl(WT) and Bcr-Abl(T315I) with K-d values of 0.32 and 0.71 nM, respectively, and strongly inhibited the kinase functions with nanomolar IC50 values. The compound potently suppressed proliferation of Bcr-Abl-positive K562 and Ku812 human CML cells with IC50 values of 0.2 and 0.13 nM, respectively. It also displayed good oral bioavailability (48.7%), a reasonable half-life (10.6 h), and promising in vivo antitumor efficacy. It induced tumor regression in mouse xenograft tumor models driven by Bcr-Abl(WT) or the mutants and significantly improved the survival of mice bearing an allograft leukemia model with Ba/F3 cells harboring Bcr-Abl(T315I). GZD824 represents a promising lead candidate for development of Bcr-Abl inhibitors to overcome acquired imatinib resistance.

  DOI：

  10.1021/jm301581y
• 作为产物：
  描述：

  3-氨基-4-甲基苯甲酸甲酯 在 盐酸 、 sodium nitrite 、 potassium iodide 作用下， 以 水 为溶剂， 反应 3.0h， 生成 3-碘-4-甲基苯甲酸甲酯
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF
  [FR] COMPOSÉ HÉTÉROCYCLIQUE AYANT UNE ACTIVITÉ INHIBITRICE DE PROTÉINE KINASE, COMPOSITION PHARMACEUTIQUE LE COMPRENANT, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途

  摘要：

  本发明涉及式（I）的化合物、包含其的药物组合物、其制备方法及其用于预防或治疗肿瘤相关的疾病或病况。

  公开号：

  WO2022188792A1

文献信息

• [EN] HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF<br/>[FR] MODULATEURS HÉTÉROCYCLIQUES DE LA SYNTHÈSE DES LIPIDES ET COMBINAISONS EN CONTENANT
  申请人：3 V BIOSCIENCES INC

  公开号：WO2015095767A1

  公开（公告）日：2015-06-25

  Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

  提供了杂环调节剂脂质合成以及其药用盐；包括这些化合物的药物组合物；以及通过给予这些化合物和其他治疗剂的组合来治疗脂肪酸合酶途径失调症状的方法。
• Solvolysis of 2-chloro-2(3,4-disubstituted) phenylpropanes: Validity of Hammett-Brown σ+ constants in assessing additive effects of substituents
  作者：Ahmed A. Taha

  DOI：10.1002/kin.20617

  日期：2012.8

  to depict such systems. The halogen substituents' extent of conformity with additivity reflected in their relative (kobsd/kcalcd) rate ratios is found to correlate with the steric size of substituents. Plots of rate ratios against Taft's steric factor of each halogen give a linear correlation coefficient of 0.994 for the 3‐halo substituents. The 3,4‐dimethyl substituents' relative rate ratio of 1.03

  这项研究的目的是测试扩展的Hammett-Brown方程log（k XX / k HH）=ρ + Σσ +的适用性，以描述令人满意的负电性含原子取代基的加和作用，已知该负电性取代基具有多种和多组分影响多取代苯的侧链反应。该方程式首次被用来关联取代基在2-氯-2-苯基丙烷（3b-3f）具有3 F，4 Me，3 Br，4 Me，3 I，4 Me，3 Me，4 Me或3 MeO，4 Me取代基。使用90％的丙酮水溶液作为溶剂，在288、298和308 K处滴定测定速率。发现这些取代基对母体枯基氯（2-氯-2-苯基丙烷）的溶剂分解速率和活化参数的测量加成效应与上述方程式具有很好的相关性。3b–3f的log（k XX / k HH）与先前针对Σσ +的研究中主要是二取代，三取代和单取代的枯基氯化物一起绘制的图给出0.990的线性相关系数，作为描述此类系统的方程有效性的量度。发现卤素取代基与它们的相对（k
• [EN] (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING<br/>[FR] DÉRIVÉS DE (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE ET COMPOSÉS ASSOCIÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA BÊTA-SÉCRÉTASE POUR LE TRAITEMENT
  申请人：COMENTIS INC

  公开号：WO2009042694A1

  公开（公告）日：2009-04-02

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

  本发明提供了新颖的β-分泌酶抑制剂及其使用方法，包括用于治疗阿尔茨海默病的方法。
• Synthesis of Methylene-Bridge Polyarenes through Palladium-Catalyzed Activation of Benzylic Carbon-Hydrogen Bond
  作者：Chien-Chi Hsiao、Yi-Kuan Lin、Chia-Ju Liu、Tsun-Cheng Wu、Yao-Ting Wu

  DOI：10.1002/adsc.201000651

  日期：2010.12.17

  In the presence of palladium(II) acetate [Pd(OAc)2] and an N-heterocyclic carbene (NHC) ligand, fluorene derivatives can be generated in good to excellent yields from 2-halo-2′-methylbiaryls through the benzylic CH bond activation (14 examples; 81–97% yields). The scope and limitations of this protocol have been examined. A wide range of functional groups, such as alkyl, alkoxy, ester, nitrile, and

  在乙酸钯（II）[Pd（OAc）2 ]和N-杂环卡宾（NHC）配体的存在下，芴衍生物可以从2-卤代2'-甲基联芳基通过苄基CH生成高至极好的收率键活化（14个例子；产率81-97％）。已经检查了该协议的范围和局限性。各种各样的官能团，例如烷基，烷氧基，酯，腈和其他，能够耐受本文的反应条件。同位素标记的联苯的环化反应产生相应的产物，具有主要的动力学同位素效应（k H / k D＝ 4.8∶1），这表明该反应的决定速率的步骤是苄基CH键的活化。此外，从三联苯中也获得了茚并芴的优异结果（3个实例；产率为91-92％）。2，6-二氯-2'-甲基联苯与二苯乙炔的级联反应通过芳基和苄基CH键的活化，以60％的收率产生了8,9-二苯基-4 H-环戊[ def ]菲。
• [EN] HEPATITIS C INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'HÉPATITE C ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2012087833A1

  公开（公告）日：2012-06-28

  This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  这份披露涉及：(a) 抑制HCV等化合物及其盐；(b) 用于制备这些化合物和盐的中间体；(c) 包含这些化合物和盐的组合物；(d) 制备这些中间体、化合物、盐和组合物的方法；(e) 使用这些化合物、盐和组合物的方法；以及(f) 包含这些化合物、盐和组合物的试剂盒。